JAHANGIR MOINI

## Focus on Pharmacology ESSENTIALS FOR HEALTH PROFESSIONALS grd edition



**Third Edition** 

# Focus on PHARMACOLOGY ESSENTIALS FOR HEALTH PROFESSIONALS



## Jahangir Moini, мо, мрн

Professor of Science and Health, Eastern Florida State College



330 Hudson Street, NY NY 10013

Vice President, Health Science and TED: Julie Levin Alexander Director of Portfolio Management: Marlene McHugh Pratt Portfolio Manager: Derril Trakalo Development Editor: Joan Gill Portfolio Management Assistant: Emily Edling Vice President, Content Production and Digital Studio: Paul DeLuca Managing Producer, Health Science: Melissa Bashe **Content Producer:** Fave Gemmellaro Project Monitor: Meghan DeMaio **Operations Specialist:** Mary Ann Gloriande Creative Director: Blair Brown Creative Digital Lead: Mary Siener Vice President, Product Marketing: David Gesell Field Marketing Manager: Brittany Hammond Full-Service Project Management and Composition: SPi Global Full-Service Project Manager: Benjamin Gilbert Inventory Manager: Vatche Demirdjian Interior Designer: Pam Verros Cover Designer: Pam Verros Cover Photo: Getty Images/zozzzo Printing and Binding: Lake Side Communications **Cover Printer:** Phoenix Color

#### Library of Congress Cataloging-in-Publication Data

Names: Moini, Jahangir, 1942- author. Title: Focus on pharmacology : essentials for health professionals / Jahangir Moini. Description: Third edition. | Upper Saddle River, New Jersey : Pearson Education, 2017. | Includes Index Identifiers: LCCN 2017000583 | ISBN 9780134525044 Subjects: | MESH: Pharmacological Phenomena | Drug Therapy | Pharmacokinetics | Allied Health Personnel Classification: LCC RM300 | NLM QV 4 | DDC 615/.1--dc23 LC record available at https://lccn.loc.gov/2017000583

Credits and acknowledgments for content borrowed from other sources and reproduced, with permission, in this textbook appear on the appropriate page within the text.

Copyright © 2018, 2013, 2008 by Pearson Education, Inc.

All rights reserved. Manufactured in the United States of America. This publication is protected by Copyright and permission should be obtained from the publisher prior to any prohibited reproduction, storage in a retrieval system, or transmission in any form or by any means, electronic, mechanical, photocopying, recording, or likewise. To obtain permission(s) to use material from this work, please submit a written request to Pearson Education, Inc., Permissions Department, One Lake Street, Upper Saddle River, New Jersey 07458 or you may fax your request to 201-236-3290.

Many of the designations by manufacturers and seller to distinguish their products are claimed as trademarks. Where those designations appear in this book, and the publisher was aware of a trademark claim, the designations have been printed in initial caps or all caps.

 $10 \hspace{0.1in} 9 \hspace{0.1in} 8 \hspace{0.1in} 7 \hspace{0.1in} 6 \hspace{0.1in} 5 \hspace{0.1in} 4 \hspace{0.1in} 3 \hspace{0.1in} 2 \hspace{0.1in} 1$ 



ISBN 13: 978-0-13-452504-4 ISBN 10: 0-13-452504-3

## Dedication

This book is dedicated to the memory of my Mother, to my wife Hengameh, my daughters Mahkameh and Morvarid, and to my granddaughters, Laila Jade and Anabelle Jasmine Mabry.

This page intentionally left blank

## **Brief Contents**



Preface vii Acknowledgments xiii About the Author xv Contributors and Reviewers xvii

## Unit 1 General Principles

- **CHAPTER 1** Introduction to Pharmacology 4
- CHAPTER 2 Pharmacodynamics 12
- CHAPTER 3 Pharmacokinetics 22
- CHAPTER 4 Drug Toxicity Pharmacogenomics 39
- **CHAPTER 5** Law and Ethics of Medications 51
- **CHAPTER 6** Terminology, Abbreviations, and Dispensing Prescriptions 65
- CHAPTER 7 Administration of Medications 82

## Unit 2 Mathematics and Dosage Calculations 104

- **CHAPTER 8** Principles of Math in Medicine 106
- CHAPTER 9 Measurement Systems and Their Equivalents 118
- **CHAPTER 10** Adult and Pediatric Dosage Calculations 130
- CHAPTER 11 Medication Errors and Prevention 149

## Unit 3 Drug Effects on Multiple Systems 164

- CHAPTER 12 Nutritional Aspects of Pharmacology 166
- **CHAPTER 13 Dietary Supplements and Alternative Therapies** 185
- CHAPTER 14 Toxicology 200
- **CHAPTER 15** Substance Abuse and Misuse 214
- CHAPTER 16 Antibacterial Agents 228
- CHAPTER 17 Antiviral Agents 257
- CHAPTER 18 Antifungal Agents 292
- CHAPTER 19 Antiprotozoal Agents 312
- CHAPTER 20 Vaccines and Immunoglobulins 329
- CHAPTER 21 Analgesic, Antipyretic, and Anti-Inflammatory Drugs 343
- CHAPTER 22 Antineoplastic Agents 365

#### vi \* Brief Contents

Unit 4	Drug Effects on Specific Systems 386
CHAPTER 23	Drugs Used to Treat Central Nervous System Conditions 388
CHAPTER 24	Drugs Used to Treat Autonomic Nervous System Conditions 418
CHAPTER 25	Anesthetic Agents 438
CHAPTER 26	Drugs Used to Treat Skin Conditions 454
CHAPTER 27	Drugs Used to Treat Cardiovascular Conditions 468
CHAPTER 28	Drugs Used to Treat Vascular Conditions 491
CHAPTER 29	Drugs Used to Treat Hyperlipidemia and Related Conditions 505
CHAPTER 30	Anticoagulants 516
CHAPTER 31	Drugs Used to Treat Fluid and Electrolyte Imbalances 531
CHAPTER 32	Drugs Used to Treat Endocrine Conditions 549
CHAPTER 33	Drugs Used to Treat Reproductive Conditions 574
CHAPTER 34	Drugs Used to Treat Gastrointestinal Conditions 592
CHAPTER 35	Drugs Used to Treat Respiratory Conditions 611
CHAPTER 36	Drugs Used to Treat Musculoskeletal Conditions 629
CHAPTER 37	Drugs Used to Treat Eye Conditions 647

## Unit 5 Special Populations 670

CHAPTER 38	Drugs Used to Treat Geriatric Patients	672
------------	--	-----

- **CHAPTER 39 Drugs Used to Treat Pediatric Patients** 684
- CHAPTER 40 Drugs Used to Treat Pregnant Patients 692

Appendices 708

- **A** Top 200 Drugs by Prescription 708
- **B** Poisons and Antidotes 714
- **C** Common Sound-Alike Drug Names 715

Glossary 719

Index 739

# Preface

The Third Edition of *Focus on Pharmacology: Essentials for Health Professionals* has been updated with the latest drug information available. It is accompanied by a new Student Workbook, which contains many different types of review questions, including multiple-choice, fill-in-the-blank, true/false, and some labeling exercises. There are seven new chapters in this edition:

- \* Chapter 2—Pharmacodynamics
- \* Chapter 3—Pharmacokinetics
- \* Chapter 4—Drug Toxicity and Pharmacogenomics
- \* Chapter 13—Dietary Supplements and Alternative Therapies
- \* Chapter 17—Antiviral Agents
- \* Chapter 19—Antiprotozoal Agents
- \* Chapter 29—Drugs Used to Treat Hyperlipidemia and Related Conditions

Other key changes and updates:

- Chapter 1 was divided into four chapters (1—Introduction to Pharmacology, 2—Pharmacodynamics, 3—Pharmacokinetics, and 4—Drug Toxicity and Pharmacogenomics).
- \* Basic Mathematics was renamed Principles of Math in Medicine.
- Nutritional Aspects of Pharmacology and Herbal Substances was divided and expanded to become Chapter 12—Nutritional Aspects of Pharmacology, and Chapter 13—Dietary Supplements and Alternative Therapies.
- Substance Abuse was renamed and expanded as Chapter 15—Substance Abuse and Misuse
- \* Antibacterial and Antiviral Agents was divided into two chapters: Chapter 16—Antibacterial Agents and Chapter 17—Antiviral Agents.
- Second-edition chapter on Antifungal, Antimalarial, and Antiprotozoal Agents was divided into two chapters: Chapter 18—Antifungal Agents, and Chapter 19— Antiprotozoal Agents.

There also have been changes to the appendices:

- \* Appendix A—The Top 200 Drugs by prescription
- \* The previous Appendix D (Immunization Schedules) was removed because it is now in the body of the book

Pharmacology is often a challenging subject for allied health students. To the rescue comes this text uniquely designed to use a *focused* approach to learning pharmacology. Introductory chapters lay the groundwork for learning this subject by explaining the history of pharmacology, discussing the legal and ethical principles involved, illustrating drug administration techniques, reviewing math, explaining drug calculations, and a discussion of medication errors and their prevention. Additionally, substance abuse is focused on in detail. The chapters that follow focus on drugs specific to body systems, pharmacotherapy of certain age groups (pediatrics and geriatrics), pharmacology for pregnant women, and broad drug categories such as antibiotics.



## **Structured Presentation of Pharmacologic Principles**

Each drug chapter focuses on drugs used to treat a certain body system and its associated disorders. The chapters open with a concise review of anatomy and physiology, providing a foundation for understanding the actions, effects, and uses of each drug. These pharmacologic principles are succinctly explained by using clearly identifiable headings in question format that help focus students' attention on the most important points about a drug class or an individual drug:

- \* How do they work?
- \* How are they used?
- What are the adverse effects? \*
- What are the contraindications and interactions? \*
- What are the most important points patients should know? \*

Sometimes these question headings focus on a class of drugs, for example, beta-adrenergic blockers. Other times, the question headings focus on a prototype (representative) drug-that is, the drug that was either the first developed in the class or is the most widely used drug in its class. Whichever approach is taken in the chapter, the five-question headings are used so students can easily focus on the key "need-toknow" drug information.

#### Focus On

#### Chloroquine

#### Chloroquine is one of the most commonly used drugs for prophylaxis and the treatment of acute malarial attacks that are caused by P. vivax, Plasmodium malariae, Plasmodium ovale, and susceptible strains of P. falciparum.

#### How does it work?

Chloroquine is a protozoacidal drug. The agent destroys *Plasmodia* organisms by interfering with their metabolism or inhibiting normal replication of the protozoan.

#### How is it used?

Chloroquine is used for the control of acute attacks of P. vivax malaria and for suppression against all plasmodia except chloroquine-resistant *P. falciparum*. The drug is neither a prophylactic nor a radical curative agent in P. vivax malaria. In regions where P. falciparum is generally sensitive to chloroquine, it is markedly effective in terminating acute attacks of nonresistant P. falcinarum malaria and usually brings about a complete cure in this type of malaria Chloroquine is the drug of choice for the oral treatment of all malaria except that caused by resistant *P. falciparum*.

#### What are the adverse effects?

Adverse effects include pigmentation of the skin and nail beds, pruritus, fatigue, toxic psychosis, and ototoxicity

#### Doxycycline

Doxycycline is also known as doxycycline calcium oral How is it used? suspension (syrup), doxycycline hyclate (capsules or film-coated tablets), and doxycycline monohydrate (for oral suspension). It is active against many different types of bacteria as well as parasites.

#### How does it work?

Doxycycline inhibits bacterial protein synthesis by binding to ribosomal subunits and is bacteriostatic against a broad range of Gram-positive and Gram-negative bacteria.

#### Chloroquine may also cause clouding of the corneas of the eves and retinopathy.

#### What are the contraindications and interactions?

Chloroquine is contraindicated in patients with liver disease, hypersensitivity to 4-aminoquinolines, psoriasis porphyria, and renal disease. This drug should also not be used by children or by pregnant or lactating women. Certain antacids and laxatives decrease chloroquine absorption, and chloroquine may interfere with the response to the rabies vaccine.

#### What are the important points patients should know?

Advise patients to promptly report visual or hearing disturbances, muscle weakness, loss of balance, and symptoms of blood dyscrasia, which include fever, sore mouth or throat, unexplained fatigue, easy bruising, or bleeding. Instruct them to wear dark glasses in sunlight and bright light because of photophobia, to reduce the risk of ocular damage, and to avoid driving or other potentially hazard-ous activities until a reaction to the drug is known. Inform patients that this drug may cause rusty yellow or brown discoloration of the urine

Doxycycline should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria, in order to reduce development of drugresistant bacteria and maintain effectiveness of this and other antibacterial drugs. This drug is primarily indicated for Rickettsial infections such as Rocky Mountain spotted fever and typhus fever and for chlamydia. Doxycycline is used for the prevention of malaria.



## **Teach-and-Test Approach**

Learning small amounts of information and testing themselves on what they've just learned is a proven way for students to retain new information. This text includes a large number of exercises, implemented in three ways: (1) *Practical Scenarios* (two per chapter) with critical thinking questions; (2) within-chapter *Apply Your Knowledge* questions; and (3) end-of-unit *Checkpoint Reviews*. This approach makes learning about pharmacology an engaging, interactive process. The Teach-and-Test approach truly differentiates the text from others and has been positively received by educators.

#### PRACTICAL SCENARIO

Each chapter concludes with two short scenarios involving fictional patients with real-life problems concerning medications. A list of two or three questions follows. These scenarios relate to the knowledge that students have gained from reading each chapter. After completing each chapter, individual students can write short answers to the questions, or the class as a whole can discuss the answers.

#### PRACTICAL SCENARIO 2

A 75-year-old man was taking several different medications for hypertension, hyperplasia of the prostate, and rheumatoid arthritis. Four of his medications were to be taken before bed, and three were to be taken in the morning. One night, he recalled that he had forgotten to take one of his medications. He got out of bed, went into his kitchen, and avoided turning on the light so as not to disturb his son-in-law, who was sleeping in the adjacent family room. In the darkness, he inadvertently took one of the medications he had already taken earlier. After 2 hours, he weke up to go to the bathroom and felt chest pain and dizziness, which caused him to collapse, awakening his wife.

#### **Critical Thinking Questions**

- Which of his medications would cause lower blood pressure, chest pain, and distinces?
- 2. What are the disadvantages of taking several drugs at the same time?



#### APPLY YOUR KNOWLEDGE

The second implementation of the "teach-andtest" approach includes exercises that are strategically placed *within* the chapters (rather than at the end). These exercise sections, called *Apply Your Knowledge*, appear after each component of the chapter content, including anatomy and physiology, and the individual pathophysiology/ pharmacology sections.

#### Apply Your Knowledge 39.1

The following questions focus on what you have just learned about pediatric pharmacokinetics. See Appendix F for answers.

#### CRITICAL THINKING

- 1. What physiologic processes may influence pharmacokinetics in children?
- 2. What are the definitions of the terms neonate, infant, and toddler?
- 3. What is the cause of kernicterus?
- What is the result of lower metabolic activities in neonates?
   Compare the GFR of newborns to older children and adults.

The exercise sections include a variety of exercises in which students need to recall and apply the content they just learned. Exercise types include fill-in-the blank, labeling, matching, and multiple-choice, as well as more pharmacology-specific exercises such as dosage calculations and drug name exercises (sound-alike and look-alike and generic-to- brand). The goal in these sections is to provide the student with an immediate review of all vital content. All drugs and drug classes mentioned in the content are "tested" in these exercise sections.



#### CHECKPOINT REVIEWS

The third component of our teach-and-test approach is unit "tests" called *Checkpoint Re*views. These review questions reflect the format on most certifying and licensing exams, and include multiple-choice and essay questions. Answers to the Apply Your Knowledge and Checkpoint Reviews are found at the end of the book in Appendix E.

#### CHAPTER SEVEN Administration of Medications \* Checkpoint Review 1 Select the best answer for the following questions. 7. Which of the following is the route of administration of a drug that is placed between the gums and the cheek? 1. The half-life is the major determinant of which of the following? a. Buccal b. Topical a. The adverse effects of a drug after a single dose b. The interaction with another single dose c. The duration of elimination of a drug after c. Sublingual d. Transdermal administration of multiple doses d. The duration of action of a drug after a single dose 8. Which of the following is a drug that was withdrawn after postmarketing surveillance Hypersensitivity is often used synonymously with which of the following terms? a. Penbutolol b. Atenolol a. Immunogen c. Furosemide b. Allergy d. Celecoxib c. Antigen d. Allergen 9. The proprietary drug name is also called the Which of the following agencies oversees controlled substances and prosecutes individuals who illegally distribute them? a. Chemical name b. Generic name c. Trade name d None of the above a. HIPAA b. FDA 10 The study of drugs derived from herbal and other c. DEA atural sources is called d. CDC a. Pharmacodynamics 4. Which of the following federal laws offers a 7-year b. Pharmacotherapy monopoly on drug sales and tax breaks to induce c. Pharmacognosy drug companies to undertake development and d. Pharmacology manufacturing of drugs used for rare diseases that affect small numbers of people in the United States? 11. Which of the following drugs carries a black box warning? a. Orphan Drug Act of 1983 a. Rifampin b. Prescription Drug Marketing Act of 1987 c. Durham–Humphrey Amendment of 1951d. Comprehensive Drug Abuse Prevention and b. Rofecoxib c. Valdecoxib d. Celecoxib Control Act of 1970 5. Which of the following phases of drug approval evalu-12. Herbal products and dietary supplements are controlled by the ates toxicology data? a. Center for Disease Control and Prevention a. Phase I h Phase II b. Center for Biologics Evaluation and Research c. Center for Food Safety and Applied Nutrition c. Phase III d. Phase IV d. Center for Drug Evaluation and Research 6. The angle of insertion for intradermal injections is 13. Which of the following can determine the dose-effect which of the following degrees relationship? a. 30 a. Pharmacodynamics b 90 b Pharmacokinetics

99

Each drug chapter includes tables of all drugs discussed in the chapter, arranged by drug classes and formatted to include generic and trade names, adult dosing, and route of administration.

**Drug Dosing Information** 

#### T-61- 17 1

c. 15

d. 45

Iable 1/-1         Examples of Effective Antiviral Agents						
GENERIC NAME	TRADE NAME	AVERAGE ADULT DOSAGE	ROUTE OF ADMINISTRATION			
acyclovir	Zovirax	<ul> <li>IV: 5–15 mg/kg q8h for 7–21 days;</li> <li>PO: 20–400 mg (800 mg max)</li> <li>4–5 times/d for 5–14 days;</li> <li>Topical: 5% cream 5 times/d for 4 days</li> </ul>	IV, PO, topical			
amantadine	Symmetrel	Two 100 mg tablets/d or 4 teaspoons of syrup/d; may be split into 1 tablet bid or 2 teaspoons of syrup bid	PO (tablets and syrup)			
didanosine	Videx, Videx EC	EC Capsules: 400 mg once/d (or 250 mg once/d with tenofovir); Oral solution: 200 mg bid	PO (enteric-coated capsules or oral solution) (take 30 minutes before meals or 2 hours after)			
ganciclovir	Cytovene, Vitrasert, Zirgan	IV infusion: 5 mg/kg over 1 hour q12h for 14–21 days; Oral: 1000 mg tid with food; Ocular implant: inserted surgically and replaced q5-8m; Ocular 0.15% gel: 1 drop in affected eye 5 times/d pm, followed by 1 drop tid for 7 days	IV, PO, ocular implant, ocular gel			
ribavirin	Virazole	20 mg/mL as starting solution in SPAG-2 unit with continuous aerosol administra- tion for 12–18 hours/d for 3–7 days (this concentration = 190 micrograms/iter of air)	Inhalation (powder for solution)			
zanamivir	Relenza	10 mg, provided in 2 inhalations using Diskhaler	Inhalation (powder for PO inhalation)			
zidovudine	Retrovir	200 mg tid or 300 mg bid	PO			
IV, intravenous; PO,	oral; bid, twice a day;	tid, three times a day.				

Both A and B

d. Pharmacology



## **Special Populations and Important Drug-Related Points**

- **\* Focus Points:** These marginal features highlight significant or difficult concepts in pharmacology.
- \* Focus on Pediatrics and Focus on Geriatrics: Each of these boxes highlights pediatric or geriatric information specific to pharmacology.
- **\* Focus on Natural Products:** This boxed feature highlights drug interactions related to complementary and alternative medicines. Herbs, supplements, and foods are included in these boxes.

#### **Focus Point**

#### Mechanism of Action of HIV Medications

T is important to understand how specific drugs used against HIV listed above. The drug called maraviroc affects Step 1, blocking H receptor. The drug called enfuvirtide blocks the fusion process of \$ drugs inhibit the reverse transcriptase enzyme's effects in Step 3. TI integrase enzyme and its effects in Step 5. Several drugs target HIV protease and its effects in Step 10.

During all stages of HIV infection, the virus replicates very quickly but particularly during the stage. This is because the amount of CD4 cells is still very large, and th response against the virus. Therefore, plasma levels of HIV can initia Patients often experience acute retroviral syndrome as a result. In the decline sharply but eventually level off to between 1,000 and 100,00 seems, since the HIV plasma half-life is 6 hours, meaning that oneevery 6 hours. Therefore, to remain a relatively steady level when infe between 1 and 10 billion virions per day. Even so, the patient is usually asymptomatic for approximately

10 years. After this period, advanced signs and symptoms appear.

HIV mutates very quickly due to errors in reverse transcriptase. incorporated into HIV DNA with each replication. Therefore, HIV can even though it was previously in a drug-sensitive form. The chance of related to the total viral load. There is more chance of at least one virid amounts of total virions. Therefore, patients are treated with combina **Focus Point** 

#### Medical Errors During the Prescribing Process

The three most common forms of prescribing errors include dosing errors, prescribing medications to which the patient has had an allergic response, and errors involving the prescribing of inappropriate dosage forms.



#### **Focus Point**



#### Heparin Injections

For subcutaneous heparin injections, make sure that 0.1 to 0.2 mL of air is in the syringe to prevent heparin leakage into tiscue. How availating leakage into tiscue. heparin leakage into tissue, thus avoiding localized hemorrhaging.

#### **Focus on Geriatrics**

#### Medications May Stain Teeth and Dentures

Advise elderly patients who have dentures to remove them before taking certain medications. Som oral liquid drugs, such as liquid iron or iodides, may stain the teeth

#### **Focus on Natural Products**

#### Lobelia Dangers

obelia is found in dietary supplements that are marketed for use by children and infants as well as L obelia is found in dietary supplements that are marketen for use by omission and alkaloids with pharmaco-pregnant women. Lobelia may be very dangerous to use because it contains alkaloids with pharmacologic actions that are similar to nicotine. It can cause autonomic nervous system depression or stimulation, bronchial dilation, increased respiratory rate, respiratory depression, sweating, rapid heart rate, hypotension, and even coma or death



Each chapter includes:

- \* Chapter Objectives
- \* Key Terms with pronunciations
- \* Chapter Capsule: A review of each chapter objective with bulleted summaries of the key information for each objective

The focused teach-and-test approach of this textbook provides allied health students with the perfect blend of concise content and an enjoyable—even fun—learning process. Pharmacology and fun have never been joined in the same sentence—until now!



## Acknowledgments



This textbook is the culmination of the efforts of many people, including my students of many years who inspired me to write it. Thank you to Julie Levin Alexander, Marlene Pratt, Derril Trakalo, and Faye Gemellaro—all of whom believed in this project from the start—and those dedicated professionals on the editorial team who helped produce this book. Melissa Bashe (Managing Content Producer) has been invaluable in helping me with the media. Joan Gill (Developmental Editor) was vital in coordinating all the steps needed to create this edition from the initial book. Many thanks to the team at SPi Global for their inspired design and excellent production process.

My special thanks go to Greg Vadimsky, who has been my personal editorial assistant from the first edition through the completion of this third edition. He also assisted me in completing the *Instructor's Manual*, student website, and PowerPoint presentations. This page intentionally left blank

## About the Author



Jahangir Moini, MD, MPH, was Assistant Professor at Tehran University School of Medicine for 9 years, teaching medical and allied health students. The author was also Professor (for 24 years) and Director (for 15 years) of allied health programs at Everest University. He was Brevard County Epidemiologist and Biological Scientist for 18 years. Dr. Moini was also Physician Liaison for the American Association of Medical Assistants (AAMA) in Florida and an Advisory Member of NACCAS. He is now Professor of Science and Health at Eastern Florida State College, and a member of their book selection and nursing student selection committees.

Dr. Moini is actively involved in teaching and helping students prepare for service in various health professions. He has been a published author of 20 allied health books since 1999. Courtes of the author

This page intentionally left blank

## Contributors/Reviewers

### CONTRIBUTORS

Karen Bills, PharmD, CPH HealthFirst, Palm Bay Hospital Palm Bay, Florida

Jeffrey R. Mabry, DMD Melbourne, Florida

Mahkameh Moini, DMD Melbourne, Florida

#### THANK YOU TO OUR REVIEWERS

#### **Reviewers of the Third Edition**

Peter F. Andrus, MD Clinical Instructor Albany Medical College Albany, New York

Carole Berube, MA, MSN, BSN, RN Bristol Community College Fall River, Massachusetts

Sara K. Daniel, MS, CHES, RHIA Arkansas Tech University Russellville, Arkansas

Pilar Perez-Jackson, CPhT, RPhT Sanford Brown Institute Iselin, New Jersey

Paula D. Silver, PharmD ECPI University Newport News, Virginia

#### **Reviewers of the Second Edition**

Elenora Alvarado Nashville State Community College Nashville, Tennessee

Sonya Burns, CMA (AAMA), BBA Augusta Technical College Waynesboro, Georgia

Sue Coleman National College Lynchburg, Virginia

Chanta Hall Mountain View College Dallas, Texas Private Practice Cleveland, Ohio Norman Tomaka, CRPh, LHCRM

Stephanie K. Mullen, RN, MSN, CPNP

HealthFirst Pharmacist Consultant Melbourne, Florida

Barbara Jareo, RN, BSN, CCM, CEN Davenport University Saginaw, Michigan

Patricia Sell, RMA(AMT), RN, AAS, BS, MSEd National College Princeton, West Virginia

Paula Silver, PharmD Medical Careers Institute Newport News, Virginia

Phaedra Spartan, RMA, BS Vatterott College Springfield, Missouri

Cindy Thompson Davenport University Saginaw, Michigan

Christy Tinnin, RN Vatterott College Fairview Heights, Illinois

Cynthia Watkins, RN, BSN Lorain County Community College Elyria, Ohio

Stephanie Weller Carrington College California Stockton, California

#### **Reviewers of the First Edition**

Patricia J. Allee, RN Blinn College Brenham, Texas Kristen Anderson, RN, BSN Southwest Wisconsin Technical College Fennimore, Wisconsin

Deborah Bedford, CMA North Seattle Community College Seattle, Washington

Susan Boggs, RN, CNOR Piedmont Technical College Greenwood, South Carolina

Vince Druash, CMA, BS Medical Careers Institute Virginia Beach, Virginia

Judy Ehninger, MA Lehigh Carbon Community College Schnecksville, Pennsylvania

Rosemary Fischer, RN, BSN, MS Alfred State College (retired) Alfred, New York

Steve Forshier, RT(R), MEd Pima Medical Institute Mesa, Arizona

Nancy D. Glass, RN, PhD Austin Community College Austin, Texas

Robyn Gohsman, RMA, CMAS, AAS Medical Careers Institute Newport News, Virginia

Henry Gomez, MD ASA Institute Brooklyn, New York

Jeanette Goodwin, CMA, BSN Southeast Community College Lincoln, Nebraska

Corrine C. Harmon, RN, MS, EdD, AOCN Clemson University Clemson, South Carolina

Elizabeth Hoffman, MAEd, CMA, CPT, (ASPT) Baker College of Clinton Township Clinton Township, Michigan

Robin Kern, RN, BSN Moultrie Technical College Moultrie, Georgia

Len Lichtblau, PhD University of Minnesota School of Nursing Edina, Minnesota

Douglas Lytle, PhD, MBA Widener University Pottstown, Pennsylvania

David Martinez, RHE, BA International Business College El Paso, Texas Nancy Matyunas, PharmD Jefferson Community & Technical College Louisville, Kentucky

Gayle Mazzocco, RN, CMA, BSN Oakland Community College Waterford, Michigan

Carol McMahon, RN, BSN, MEd Capital Community College Simsbury, Connecticut

Michele G. Miller, MEd, CMA, COMT Lakeland Community College Kirtland, Ohio

Lisa Nagle, BSed, CMA Augusta Technical College Augusta, Georgia

Eva Ruth Oltman, CMA, CPC, EMT, LMR, MA Kentucky Community & Technical College System Prospect, Kentucky

Christopher Owens, PharmD, BCPS Idaho State University Pocatello, Idaho

Steve Peterson, CPhT, MEd Apollo College Scottsdale, Arizona

Diane Premeau, RHIA, CHP, MBA Chabot College Fremont, California

Myra Resnick, RN Southwestern College Florence, Kentucky

Jackie Smith, RN, CPhT National College of Business and Technology Pounding Mill, Virginia

Karen Snipe, CPhT, MAEd Trident Technical College Charleston, South Carolina

Pat Stroupe, RN, MSN Waukesha County Technical College Pewaukee, Wisconsin

Joe Tinervia, CPhT, MBA Community Care College Tulsa, Oklahoma

Robert Tralongo, RRT-NPS, MBA Molloy College Rockville Centre, New York

Jana Tucker, CMA, LPRT Salt Lake Community College Salt Lake City, Utah

Gail Tuohig, RN, PhD St. Mark's Hospital Salt Lake City, Utah Lori Warren, RN, CPC, CCP, CLNC, MA Spencerian College Louisville, Kentucky

Tonia Webster, RN, CMA Southwest Wisconsin Technical College Platteville, Wisconsin

Mary Ann Woods, RN, CMA, MS, PhD Fresno City College Fresno, California

Judith Wulff, RN, BSN D.G. Erwin Technical Center Tampa, Florida

#### **MEDIA REVIEWERS**

#### **Reviewers of the Third Edition Media**

Peter F. Andrus, MD Albany Medical College, Albany, New York

Carole Berube, MA, MSN, BSN, RN Bristol Community College Fall River, Massachusetts

Sara K. Daniel, MS, CHES, RHIA Arkansas Tech University Russellville, Arkansas

Pilar Perez-Jackson, CPhT, RPhT Sanford Brown Institute Iselin, New Jersey

Paula D. Silver, PharmD. ECPI University: College of Health Science Newport News, Virginia

#### **Reviewers of the Second Edition Media**

Sonya Burns, CMA (AAMA), BBA Augusta Technical College Waynesboro, Georgia

Barbara Jareo, RN, BSN, CCM, CEN Davenport University Saginaw, Michigan

Patricia Sell, RMA(AMT), RN, AAS, BS, MSEd National College Princeton, West Virginia

Paula Silver, PharmD. Medical Careers Institute Newport News, Virginia

Phaedra Spartan, RMA, BS Vatterott College Springfield, Missouri Cindy Thompson Davenport University Saginaw, Michigan

Christy Tinnin, RN Vatterott College Fairview Heights, Illinois

Cynthia Watkins, RN, BSN Lorain County Community College Elyria, Ohio

#### **Reviewers of the First Edition Media**

Joyce B. Benedetti, RN, MS, JD, CMA-AC Allan Hancock College Santa Maria, California

Peggy Bush, PhD, RPh Durham Technical Community College Durham, North Carolina

Carol Buttz Dakota County Technical College Rosemount, Minnesota

Jennifer Chang, BS, MS College of Marin Kentfield, California

June A. Griffith, PharmD, CGP Florida Community College Jacksonville, Florida

Lynda Harkins, PhD Texas State University–San Marcos San Marcos, Texas

Anne P. LaVance, BS, CPhT Delgado Community College New Orleans, Louisiana

Vivian C. Lilly, PhD, MBA, RN North Harris College Houston, Texas

Patricia McLane, RHIA, MA Schoolcraft College Garden City, Michigan

Michele G. Miller, MEd, CMA, COMT Lakeland Community College Kirtland, Ohio

Lisa Nagle, BSed, CMA Augusta Technical College Augusta, Georgia

Geraldine Twomey, MEd, RRT, RN North Shore Community College Danvers, Massachusetts This page intentionally left blank

## Contents

Preface vii Acknowledgments xiii About the Author xv Contributors and Reviewers xvii

## Unit 1 General Principles 2

CHAPTER 1 Introduction to Pharmacology 4 Introduction 5 Classification of Drugs 5 The Food and Drug Administration 6 Drug Approval 6

CHAPTER 2 Pharmacodynamics 12 Introduction 13 Pharmacodynamics 13

- CHAPTER 3 Pharmacokinetics 22 Introduction 23 Movement of Drugs Across Plasma Membranes 23 Drug Absorption 25 Drug Distribution 27 Drug Metabolism 28
- CHAPTER 4 Drug Toxicity and Pharmacogenomics 39 Introduction 40 Drug Toxicity 40 Adverse Effects 40 Pharmacogenomics 41 Physical Dependence 43 Teratogenic Effects 43 Carcinogenic Effects 43 Hepatotoxic Effects 43 Hypersensitivity Reaction 45 Drug–Drug Interactions 47
- CHAPTER 5Law and Ethics of Medications51Introduction52The Need for Drug Control52



Federal Law 52 The Durham-Humphrey Amendment of 1951 53 Federal Regulatory Agencies 60 State Law 61 Ethics in Clinical and Pharmacy Practice 61

#### CHAPTER 6 Terminology, Abbreviations, Drug Forms, and Dispensing Prescriptions 65

Introduction 66 Pharmaceutical Terminology 66 Abbreviations Used in Pharmacology 66 Drug Names 68 Sources of Drug Derivation 68 Removal of a Drug from the Market 70 Black Box Warnings 70 Drug Forms 70 Dispensing Drugs 76

CHAPTER 7Administration of Medications82Introduction83Principles of Drug Administration83Routes of Drug Administration85

Checkpoint Review 1 99

## Unit 2 Mathematics and Dosage Calculations

#### CHAPTER 8 Principles of Math in Medicine 106

Introduction 107 Arabic System and Roman Numeral System 107 Using Numbers for Calculations 107

104

CHAPTER 9	Measurement Systems and Their Equivalents 118		Food Additives and Contaminants 181
	Introduction 119 Units of Measure 119 Temperature Conversions 122 Time Conversions 124 Milliequivalents and Units 125	CHAPTER 13	<b>Dietary Supplements</b> <b>and Alternative Therapies 185</b> Introduction 186 Herbal Supplements 186
	Conversion Within and Between Systems 125		Legislation Concerning Supplements 187
CHAPTER 10	Adult and Pediatric Dosage Calculations 130		Nonherbal Supplements 191 Alternative Therapies 192
	Introduction 131 General Dosage Calculations 131	CHAPTER 14	<b>Toxicology 200</b> Introduction 201
CHAPTER 11	Medication Errors and Prevention 149		Poisoning 201 Common Poisons 202
	Introduction 150 Medication Errors 150		Antidotes 209 Prevention 209
	Causes of Medication Errors151Results of Medication Errors151		Poison Control Centers 210
	Documentation of Medication Errors 152	CHAPTER 15	Substance Abuse and Misuse 214 Introduction 215
	Reporting Medication Errors 152 Sentinel Events 153 Reducing and Preventing Medication		Substance Abuse 215 Substance Misuse 215 Addictive Drugs 215
	Errors 153 Strategies for Handling Medication Errors 154		Central Nervous System Depressants 216
	Reconciling Medications 155 Patient Education About Medications 155		Cannabinoids 217 Hallucinogens 218 Central Nervous System Stimulants 219
Checkpoint Re	view 2 160		Effects of Substance Abuse 220 Prevention and Treatment 221
Unit 3	Drug Effects		Cigarette Smoking 221 Alcoholism 223
	on Multiple	CHAPTER 16	Antibacterial Agents 228
CHAPTER 12	Systems   164     Nutritional Aspects		Introduction 229 Transmission of Infection 229 Types of Microorganisms 230

of Pharmacology 166 Introduction 167 Nutrients 167 Macronutrients 167 Micronutrients 169 Nutritional Requirements 179 Nutritional Support 179 Nutrient–Drug Interactions 180

## Antiviral Agents 257 **CHAPTER 17**

Introduction 258 Virus Characteristics 258

Antibacterial Agents 231

Factors of Antibacterial

Effectiveness 253

Antituberculosis Agents 250

Antiviral Agents 258 HIV Infections 258 HIV Infection Development Process 262 Antiretroviral Drugs 263 Non-Nucleoside Reverse Transcriptase Inhibitors 270 Protease Inhibitors 274 Integrase Strand Transfer Inhibitors 281 Fusion Inhibitors 281 Chemokine Receptor 5 Antagonists 281 Other Antiviral Agents 281

#### CHAPTER 18 Antifungal Agents 292

Introduction 293 Fungal Characteristics 293 Fungal Infections 293 Antifungal Agents 294

#### CHAPTER 19 Antiprotozoal Agents 312

Introduction 313 Protozoal Infections 313

#### CHAPTER 20 Vaccines and

Immunoglobulins 329 Introduction 330 The Immune System 330 Cell-Mediated Immunity and Humoral Immunity 330 Immunity 332 Immunizing Agents 332 Standards for Childhood Immunization 334 Standards of Immunization for Adults Age 65 and Under 336 Standards of Immunization for Adults Age 65 and Older 337

#### CHAPTER 21 Analgesic, Antipyretic, and Anti-Inflammatory Drugs 343

Introduction 344 What Is Pain? 344 Nonsteroidal Anti-Inflammatory Drugs 345 Migraine 352 Opiates 353 Semisynthetic Opioid Analgesics 357 Synthetic Opioid Antagonists358Synthetic Opioid Analgesics359

#### CHAPTER 22 Antineoplastic Agents 365 Introduction 366 Neoplasms 366 What Causes Cancer? 366

Cancer Therapy 368

Checkpoint Review 3 382

## Unit 4 The Effects of Drugs on Specific Systems 386

#### CHAPTER 23 Drugs Used to Treat Central Nervous System Conditions 388

Introduction 389 The Nervous System 389 Anxiety 391 Insomnia 391 Attention-Deficit Disorder and Attention-Deficit/Hyperactivity Disorder 395 Epilepsy 395 Alzheimer's Disease 400 Parkinson's Disease 403 Schizophrenia and Psychotic Disorders 406 Mood Disorders 407 Depression 410

#### CHAPTER 24 Drugs Used to Treat Autonomic Nervous System Conditions 418

Introduction 419 Anatomy of the Autonomic Nervous System 419 Sympathetic Nervous System 419 Parasympathetic Nervous System 419 Neurotransmitters of the Autonomic Nervous System 419

#### CHAPTER 25 Anesthetic Agents 438

Introduction 439 Anesthesia 439 Stages of Anesthesia 439 Preoperative Medications as Adjuncts to Surgery 440 General Anesthetics 441 **CHAPTER 26** Drugs Used to Treat Skin Conditions 454 Introduction 455 The Skin 455 Disorders of the Skin 455 Bacterial Skin Infections 461 Fungal Infections 462 Scabies and Pediculosis 463 **CHAPTER 27 Drugs Used to Treat Cardiovascular Conditions** 468 Introduction 469 The Cardiovascular System 470 Coronary Heart Disease 471 Myocardial Infarction 475 Dysrhythmias 476 Congestive Heart Failure 484 **CHAPTER 28 Drugs Used to Treat Vascular Conditions** 491 Introduction 492 The Vascular System 492 Hypertension 493 **CHAPTER 29** Drugs Used to Treat Hyperlipidemia and Related Conditions 505 Introduction 506 Major Plasma Lipids 506 Lipoprotein Metabolism 506 Hyperlipidemia 506 **CHAPTER 30** Anticoagulants 516 Introduction 517 Hemostasis 517 Anticoagulants 518 **CHAPTER 31 Drugs Used to Treat Fluid** and Electrolyte Imbalances 531 Introduction 532 Kidney Structure and Functions 532 Fluid and Electrolyte Balance 536 **Drugs Used to Treat Endocrine CHAPTER 32** Conditions 549 Introduction 550

Endocrine System 550

Pituitary Gland 550

Thyroid Gland 554 Pancreas 559 Adrenal Glands 567

#### **CHAPTER 33 Drugs Used to Treat Reproductive** Conditions 574

Introduction 575 Male Reproductive System 575 Female Reproductive System 578 Contraception 582 Labor and Delivery 586

#### **CHAPTER 34 Drugs Used to Treat Gastrointestinal Conditions** 592

Introduction 593 The Digestive System 593 Peptic Ulcers 594 Diarrhea 599 Constipation 601 Vomiting 605

#### **CHAPTER 35 Drugs Used to Treat Respiratory Conditions 611**

Introduction 612 Organs of the Respiratory System 612 Asthma 612

#### CHAPTER 36 **Drugs Used to Treat** Musculoskeletal Conditions 629

Introduction 630 Musculoskeletal System 630 Osteoporosis 631 Rheumatoid Arthritis 634 Gout and Gouty Arthritis 638 Muscle Spasms and Pain 641

**CHAPTER 37 Drugs Used to Treat Eye** Conditions 647 Introduction 648 Structure and Function of the Eye 648 Disorders of the Eye 649 Drug Therapy for Minor

**Checkpoint Review 4** 

661

Eye Conditions 657

## Unit 5 Special Populations 670

#### CHAPTER 38 Drugs Used to Treat Geriatric Patients 672

Introduction 673 Geriatric Drug Therapy 673 Disease and Death in Older Adults 673 Physiologic Changes in Older Adults 673 Changes in Pharmacokinetics 673 Changes in Pharmacodynamics 675 Changes in the Effects of Drugs on Elderly Patients 676 Special Considerations 680

#### CHAPTER 39 Drugs Used to Treat Pediatric Patients 684

Introduction 685 Pharmacokinetics 685 Pediatric Dosage Forms and Compliance 686 Pharmacodynamics 687 Drug Administration During Lactation 688 Pediatric Drug Dosages 688

#### CHAPTER 40 Drugs Used to Treat Pregnant Patients 692

Introduction 693 Health and Development 693 Pregnancy Drug Categories and Registries 694 Pregnancy Registries 694 Toxic Effects and Responses 696 Pharmacokinetics 696 Drug Effects on the Newborn 697 Drugs Used During Pregnancy 698 Pharmacotherapy During Lactation 699 Recreational Drugs 700 Vaccinations During Pregnancy and Lactation 702

#### Checkpoint Review 5 706

Appendices 708

- **A** Top 200 Drugs by Prescription 708
- **B** Poisons and Antidotes 714
- **C** Common Sound-Alike Drug Names 715

#### Glossary 719

Index 739

# UNIT



# General Principles



To administer a drug safely, one must know its usual dose, frequency, route of administration, indications, contraindications, significant adverse reactions, and major drug interactions.

# Chapter

# Introduction to Pharmacology

#### **Chapter Objectives**

After completing this chapter, you should be able to:

- 1. Compare and define pharmacognosy and pharmacotherapeutics.
- 2. Define *drugs* and *CAM* therapies.
- 3. Compare prescription drugs with over-the-counter drugs.

#### **Key Terms**

biologics (p. 5) black box warning (p. 8) complementary and alternative medicine (CAM) therapies (p. 5) dose (p. 5) drug (p. 5) medication (p. 5) NDA review (p. 8)

- 4. Explain biologic agents and give four examples.
- **5.** Describe the role of the Food and Drug Administration.
- 6. Explain drug approval.
- 7. Describe the longest stage of drug approval.
- 8. Define postmarketing surveillance.

pharmacognosy (p. 5) pharmacology (p. 5) pharmacotherapeutics (p. 5) prescription (p. 5)

## Introduction

**Pharmacology** is the study of drugs, including their action and effects in living body systems. Clinical pharmacology is the study of drugs in humans. It is involved with all aspects of the interaction between drugs and patients. The term *drug* is defined as "any substance or product that is used or intended to be used to modify or improve a physiologic or pathologic condition." The terms *medication* and *medicine* refer to drugs mixed in a formulation with other ingredients to improve the stability, taste, or physical form to allow appropriate administration of the active drug.

Pharmacology deals with all the types of drugs used in society today (legal, illegal, prescription, and overthe-counter [OTC] medications). To administer a drug safely, one must know its usual **dose**, frequency, route of administration, indications, contraindications, significant adverse reactions, and major drug interactions. Knowledge of the patient's medication allergies, weight, and liver and kidney functions is also essential.

**Pharmacognosy** is the study of drugs derived from herbal and other natural sources. By studying the compositions of natural substances and how the body reacts to them, one gains better knowledge for developing purified versions. **Pharmacotherapeutics** is the study of how drugs may be best used in the treatment of illnesses and which drug is most or least appropriate to use for a specific disease. In this chapter, I consider classifications of prescription and over-the-counter drugs, the role of the FDA, and drug approval.

## **Classification of Drugs**

Therapeutic agents may be classified as drugs (medications), biologics, or complementary and alternative medicine (CAM) therapies.

- \* A **drug** is any agent that produces biologic responses within the body. When a drug response is desired, it is referred to as *therapeutic*. When the response is undesired, it is referred to as *adverse*. Once a drug has been administered to a patient, it is referred to as a **medication**, yet both drugs and medications are thought of as components of normal physiological activities. Drugs differ from other products such as cosmetics, foods, and household chemicals, such as toothpaste, shampoo, and others.
- Biologics are agents produced inside animal cells from the actions of microorganisms, or by the entire body itself. They are natural substances, whereas most drugs used today are synthesized in laboratories. Biologics treat many different conditions or illnesses, and include hormones, vaccines, interferons, monoclonal antibodies, and natural blood products.
- \* Complementary and alternative medicine (CAM) therapies use herbs, plant extracts, dietary supplements, vitamins, and minerals. Additionally, therapies such as acupuncture, massage, hypnosis, and biofeedback are also considered CAM therapies.

## Apply Your Knowledge 1.1

The following questions focus on what you have just learned about drug classifications.

#### **CRITICAL THINKING**

- 1. Describe biologic drugs.
- 2. Define complementary and alternative medicine therapies.
- 3. What is the definition of a medication?

#### PRESCRIPTION DRUGS

Prescription agents are legal drugs that can only be dispensed using a prescription from an authorized health practitioner. A **prescription** is an order, usually written, for medications or other therapies to be supplied to a specific individual patient. They are based on examinations and diagnoses of patients by physicians, nurse practitioners, and other health practitioners. Prescriptions contain dosage information that is designed to provide the most accurate treatment for the diagnosed condition. Another advantage of using prescription agents is that, should there be any interactions with other drugs, supplements, or foods, the health care practitioner is able to ascertain the safe use of what is being prescribed for the patient. Sometimes, usage of a prescription medication over many years, with little or no safety concerns resulting, means that the medication may later become available over the counter (OTC).